1307233-94-8

Basic information

• Product Name: ethyl 3-(2-(chloroMethyl)-1-Methyl-N-(pyridin-2-yl)-1H-benzo[d]iMidazole-5-carboxaMido)propanoate
• Synonyms: ethyl 3-(2-(chloroMethyl)-1-Methyl-N-(pyridin-2-yl)-1H-benzo[d]iMidazole-5-carboxaMido)propanoate;N-[[2-(Chloromethyl)-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-beta-alanine ethyl ester;Ethyl 3-(2-(chloromethyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propano
• CAS NO: 1307233-94-8
• Molecular Formula: C₂₀H₂₁ClN₄O₃
• Molecular Weight: 402.87462
• Mol File: 1307233-94-8.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 609.5±55.0 °C(Predicted)
• Appearance: /
• Density: 1.29
• PKA: 3.71±0.10(Predicted)
• CAS DataBase Reference: ethyl 3-(2-(chloroMethyl)-1-Methyl-N-(pyridin-2-yl)-1H-benzo[d]iMidazole-5-carboxaMido)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3-(2-(chloroMethyl)-1-Methyl-N-(pyridin-2-yl)-1H-benzo[d]iMidazole-5-carboxaMido)propanoate(1307233-94-8)
• EPA Substance Registry System: ethyl 3-(2-(chloroMethyl)-1-Methyl-N-(pyridin-2-yl)-1H-benzo[d]iMidazole-5-carboxaMido)propanoate(1307233-94-8)

Safety Data

• Hazardous Substances Data: 1307233-94-8(Hazardous Substances Data)

Usage

Description

Ethyl 3-(2-(chloromethyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate is a complex organic compound that serves as a crucial intermediate in the synthesis of dabigatran etexilate, a direct thrombin inhibitor used for the prevention and treatment of various thromboembolic disorders.

Uses

Used in Pharmaceutical Industry:
Ethyl 3-(2-(chloromethyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate is used as a key intermediate in the synthesis of dabigatran etexilate for its role as a direct thrombin inhibitor. Ethyl 3-(2-(chloromethyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate is essential in the development of medications that help prevent and treat thromboembolic events, such as deep vein thrombosis, pulmonary embolism, and stroke, in patients with atrial fibrillation or following orthopedic surgery.
The compound's significance in the pharmaceutical industry lies in its contribution to the production of dabigatran etexilate, which has proven to be an effective alternative to traditional anticoagulants like warfarin. Dabigatran etexilate offers a more predictable anticoagulant effect, fewer drug interactions, and no requirement for routine coagulation monitoring, making it a preferred choice for many patients and healthcare providers.

Upstream product

• 51076-95-0 2-chloro-1,1,1-triethoxyethane 
• 212322-56-0 ethyl 3-{[{2-amino-1-(methylamino)phen-4-yl}carbonyl](pyridyn-2-yl)amino}propanoate 

Downstream Products

• 211915-06-9 dabigatran etexilate 
• 1408238-40-3 ethyl 3-[[[2-[[[4-[[[(hexyloxy)carbonyl]amino]carbonyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino]propanoate 
• 872728-81-9 N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl] amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-(2-pyridinyl)-β-alanine ethyl ester methanesulfonate 
• 429658-95-7 3-({2-[(4-carbamimidoylphenylamino)methyl]-1-methyl-1H-benzoimidazole-5-carbonyl}pyridin-2-yl-amino)propionic acid ethyl ester 

Relevant articles and documents

Preparation method of Pradaxa intermediate

The invention belongs to the technical field of medicine preparation, and particularly relates to a preparation method of a Pradaxa intermediate. An adopted compound 6 has the characteristics of stable properties, no irritating odor, low price and the like. The defects that acid anhydride or acyl chloride compounds having the disadvantages of irritating odor, hygroscopicity and a high requirementfor an anhydrous reaction system are adopted in an existing synthesis route of the Pradaxa intermediate can be overcome. The reaction process has easier operation and control, high selectivity and stable yield.